Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children by Susanna Esposito, Nicola Principi

“…Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. …”
Get full text

Respiratory Infection and Otitis Media Visits in Relation to Pneumococcal Conjugate Vaccine Use in Saskatchewan by Ngoc-Hang Khuc, Ben Tan, Rosalie Tuchscherer, Nigel SB Rawson, Philippe De Wals

“…BACKGROUND: In Saskatchewan, pneumococcal conjugate vaccination (PCV) was offered to high-risk children in 2002 and to all infants in 2005.…”
Get full text

Delayed completion of pneumococcal conjugate vaccination among children 4–48 months in rural Uganda: a socio-demographic inquiry by Herbert Malemo, Andrew Tamale, Paul Kakwangire, Matthew C. Igwe, Dickens R. Mwine, Isa Asiimwe, Solomon A. Mbina, Mary G. Abalinda

“…Abstract In spite of the commendable global Pneumococcal Conjugate Vaccine (PCV) coverage in the last two decades, completion and timeliness of receipt of all the required doses are still below target. …”
Get full text

Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7) by Javier Nieto Guevara, Carlos Daza, Rebecca Smith

“…This study quantifies the impact of Heptavalent-Pneumococcal Conjugate Vaccine (PCV7) in Panama on indigenous children younger than 5 years old, based on clinical pneumonia cases. …”
Get full text

A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015 by Ting-An Yen, Jhong-Lin Wu, Chi-Chuan Wang, Ling-Ya Huang, See-Hwee Yeo, Dony Patel, Cindy Thiow Koon Lim, Hung-Wei Lin, Eriko Yamada, Isaya Sukarom

Subjects: “…Pneumococcal conjugate vaccine…”
Get full text

Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study by Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L. Cutland, Shabir A. Madhi

Subjects: “…Pneumococcal conjugate vaccines…”
Get full text

Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2) by Tao Chen, Duolao Wang, Konstantinos Liatsikos, Stephen B Gordon, Hassan Burhan, Ben Morton, Tinashe K Nyazika, Bradford D Gessner, Helen Hill, Andrea Collins, Josh Hamilton, Kelly Davies, Fred Fyles, Phoebe Hazenberg, Elizabeth Begier, Angela Hyder-Wright, Sherin Pojar, Christopher Myerscough, Jesus Reine, Ryan E Robinson, Britta Urban, Elena Mitsi, Carla Solorzano, Angela Quinn, Kaijie Pan, Annaliesa S Anderson, Christian Theilacker, Daniela M Ferreira, Kelly Convey, James Court, Madlen Farrar, Lisa Hitchins, Ashleigh Howard, Lauren Kerruish, Samuel Latham, Annabel Murphy, Elissavet Nikolaou, Angelina Peterson

“…Here, we summarise an ethically approved protocol for a double-blind, randomised controlled trial investigating the effect of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23) on pneumococcal nasopharyngeal colonisation acquisition, density and duration using experimental human pneumococcal challenge (EHPC).Methods and analysis Healthy adult participants aged 18–50 years will be randomised to receive PCV13, PPV23 or placebo and then undergo one or two EHPCs involving intranasal administration of SPN at 1-month post-vaccination with serotype 3 (SPN3) and 6 months with serotype 6B (SPN6B). …”
Get full text

Pneumococcal Tricuspid Valve Endocarditis in a Young African American: A Case for Inclusion of African Americans in Pneumococcal Vaccine Criteria by Oghenerukevwe Odiete, Olagoke Akinwande, John J. Murray, Joseph Akamah

“…This case will illustrate the high susceptibility for invasive pneumococcus sequelae in AA, thereby raising the argument for the consideration of AA in the Pneumococcal Conjugate Vaccine (PCV) criteria, regardless of smoking history.…”
Get full text

Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992–2008) by Matthias Imöhl, Ralf René Reinert, Mark van der Linden

“…No increase was observed concerning serotype 19A. Higher pneumococcal conjugate vaccine coverages were observed among children (7v, 57.3%; 10v, 72.8%; 13v, 83.5%) than among adults (7v, 39.9%; 10v, 55.5%; 13v, 73.5%). …”
Get full text

Serotypes and antimicrobial resistance of Streptococcus pneumoniae in Chinese pediatric population: a scoping review by Xu Han, Haiyang Yu, Niurka Molina Águila, María Eugenia Toledo Romaní

“…It is concluded that the pneumococcal conjugate vaccine 13 has high coverage in Streptococcus pneumoniae serotypes in children from mainland China, therefore its inclusion in the childhood vaccination program is recommended; at the same time, the occurrence of serotype substitution should be taken into account. …”
Get full text

Nasopharyngeal Bacterial Carriage in the Conjugate Vaccine Era with a Focus on Pneumococci by V. T. Devine, J. M. Jefferies, S. C. Clarke, S. N. Faust

“…Seven-valent pneumococcal conjugate vaccine (PCV7) was included in the UK national immunisation program in 2006, and this was replaced by thirteen-valent PCV in 2010. …”
Get full text

Changes and determinants of pneumococcal vaccine uptake in Ethiopia. by Biniyam Tedla Mamo, Ferehiwot Gebrehiwot Geram, Kebron Yihenew Getnet, Zelalem Tazu Bonger

“…The percentage change in pneumococcal conjugate vaccine (PCV) coverage was used to quantify the degree of change over time, while multilevel ordinal logistic regression identifies significant factors. …”
Get full text

Vaccine Prophylaxis of Pneumococcal Infections in Children under Conditions of Severe Flood in the Amur River Basin by Aleksandr G. Chuchalin, Gennadiy G. Onishchenko, Victor P. Kolosov, Olga P. Kurganova, Tatiana A. Zaitseva, Leonid G. Manakov, Galina N. Kholodok, Juliy M. Perelman, Roman S. Kozlov, Natalia M. Ivakhnishina, Olga E. Trotsenko, Albina P. Bondarenko

“…The monitoring program includes children aged 2 to 5 years in the amount of 4988 with risk factors for pneumococcal infection. The pneumococcal conjugate vaccine Prevenar-13 was used for immunization. …”
Get full text

Implementation of a Targeted Technologic Screening Tool to Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies: A Quality Improvement Initiative by Annika Skogg, Alicia Zagel, R. May O'Donnell, Ann Philbrick, Mary Nelson, Allyson Schlichte, Kassie Klasen

“…Recently, pneumococcal vaccination guidelines for adults were updated to include new pneumococcal conjugate vaccines (PCV20), taking into consideration age, underlying risk factors, and previous vaccine status. …”
Get full text

Establishing a new human pneumococcal standard reference serum, MPRSS-01 by Joseph M. Antonello, Rocio D. Murphy, Chitrananda Abeygunawardana, Juliana C. Malinverni, Rajam Gowrisankar, Tina Green, Rebecca Greway, Jenna Schmauch, Adrienne Howlett, Cyrille J. Bonhomme, Katrina M. Nolan

“…Development of new pneumococcal conjugate vaccines (PCVs) with additional serotypes not in 007sp (e.g., V116, a 21-valent PCV) requires a new reference serum. …”
Get full text